The silencing of STAT3 by shRNA in HER2 overexpressing breast cancer cells resulted in a reduction in CD44-positive cells and the downregulation of the expression of stem cell markers, such as Octamer-binding transcription factor (OCT-4) and SRY (sex determining region Y)-box 2 (SOX-2). This evidence concerns the gene ERBB2 and breast carcinoma.